Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258816 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL12259083 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL1911484 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDNPC1 | |
| SCHEMBL741956 | 0.90 | MAPT (0.61) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7326780 | 0.88 | MAPT (0.59) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14003361 | 0.86 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL24109315 | 0.83 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL29071505 | 0.83 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL6081128 | 0.82 | MAPT (0.56) | MAPTALDH1A1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL25897048 | 0.81 | MAPT (0.54) | MAPTALDH1A1KDM4ETSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-05-23 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | MAPT 4140/4885ALDH1A1 3567/4885SMN1; SMN2 2810/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | MAPT 4140/4885ALDH1A1 3567/4885SMN1; SMN2 2810/4885 |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | MAPT 4140/4885ALDH1A1 3567/4885SMN1; SMN2 2810/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | MAPT 2382/4885ALDH1A1 301/4885SMN1; SMN2 3106/4885 |
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | PDCD1, CD274, PDCD1LG2 | MAPT 793/4885ALDH1A1 26/4885SMN1; SMN2 3068/4885 |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, SERPINB1, KLK5 | MAPT 4140/4885ALDH1A1 3567/4885SMN1; SMN2 2810/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | MAPT 3235/4885ALDH1A1 4236/4885SMN1; SMN2 2633/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | MAPT 2512/4885ALDH1A1 534/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.